Morgan Stanley analyst Ricky Goldwasser upgraded Cardinal Health to Equal Weight from Underweight with a price target of $64, up from $48. Shares of Cardinal, the third largest distributor of pharmaceuticals and medical supplies in the U.S., have underperformed the S&P in the last five years, noted Goldwasser. However, she now has increased confidence in management's ability to deliver on guidance and accelerating earnings into 2021 given improving generic sourcing trends and medical segment margin expansion that she views as sustainable, the analyst tells investors.